US Patent

US11351166 — Methods for treating antipsychotic-induced weight gain

Method of Use · Assigned to Alkermes Pharma Ireland Ltd · Expires 2031-08-23 · 5y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for reducing weight gain associated with the use of atypical antipsychotic medications, such as Zyprexa.

USPTO Abstract

The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.

Drugs covered by this patent

Zyprexa (olanzapine) · Eli Lilly

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3140`	—	Zyprexa
`U-3140`	—	Zyprexa
`U-3140`	—	Zyprexa
`U-3140`	—	Zyprexa

Patent Metadata

Patent number: US11351166
Jurisdiction: US
Classification: Method of Use
Expires: 2031-08-23
Drug substance claim: No
Drug product claim: No
Assignee: Alkermes Pharma Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.